Diversey’s Oxivir 1 gets C. Auris claim for Oxivir 1

In a recent press release, Diversey announced that the Environmental Protection Agency (EPA) has approved the addition of Candida auris (C. auris) to the master label of Oxivir® 1, in both its ready-to-use and wipes formats.

Advertisement

Oxivir 1 is effective against C. auris and a broad spectrum of pathogens in just 1 minute.

 Oxivir 1 is the first non-bleach disinfectant specifically approved as effective against C. auris by the EPA. The EPA recognizes that C. auris is a serious public health threat, particularly in healthcare settings, and until now, there have been no EPA-approved products specifically registered to control C. auris. Oxivir 1 products have now been tested and passed EPA’s review to secure registration of this emerging, and difficult-to-kill pathogen. This applies to both RTU and Wipes, EPA registration Nos. 70627-74 and 70627-77, respectively.

Click here to continue>>

 

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.